Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation protects vulnerable infants

RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”

The pregnancy vaccine operates by stimulating the mother’s immune system to generate protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, precisely when they are most vulnerable to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence indicating that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.

• Nearly 85 per cent coverage when immunised 4 weeks before birth
• Antibodies from the mother transferred through the placenta protect newborns from day one
• Protection possible with two-week gap before premature birth
• Vaccination during the third trimester still offers significant protection for infants

Compelling evidence from the latest research

The effectiveness of the pregnancy RSV vaccine has been established through a comprehensive study undertaken in England, examining data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month period, providing robust and representative information of the vaccine’s actual performance. The study’s results have been validated by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scale of this research gives healthcare professionals and expectant parents with confidence in the vaccine’s demonstrated effectiveness across different groups and contexts.

The results reveal a striking picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This marked difference underscores the vaccine’s essential role in preventing serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.

Study design and parameters

The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection rates and hospitalisations. The large sample size and thorough nature of the data gathering ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or limited subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology measured actual clinical results rather than experimental conditions, providing practical evidence of how the vaccine functions when given across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.

Learning about RSV and its risks

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.

The infection triggers inflammation deep within the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed properly. Parents commonly see their babies struggling visibly, their chests heaving as they attempt to draw sufficient oxygen into their compromised lungs. Whilst the majority of babies get better with palliative treatment, a limited though important proportion perish from RSV complications yearly, making prevention through vaccination a essential public health objective for safeguarding the most vulnerable and youngest individuals in the population.

• RSV causes inflammation in lungs, leading to serious respiratory problems in babies
• Half of all infants acquire the virus during their first few months alive
• Symptoms range from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
• More than 20,000 UK infants require serious hospital care for RSV annually
• A small number of infants succumb to RSV complications each year in the UK

Uptake rates and professional guidance

Since the RSV vaccine programme commenced in 2024, health officials have highlighted the significance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing matters greatly for ensuring newborns receive the most robust immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery provides nearly 85% protection, experts advise women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies through the placenta.

The messaging from health authorities stays clear: pregnant women should prioritise vaccination during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy acknowledges the practical demands of pregnancy whilst maintaining strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.

Regional differences in immunisation

Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Some areas have achieved higher vaccination coverage among eligible pregnant women, whilst others continue working to increase awareness and availability of the jab. These regional differences reflect differences across medical facilities, communication strategies, and local engagement efforts, though the national data demonstrates consistently strong protection irrespective of geographical location.

• NHS trusts deploying diverse outreach initiatives to engage with expectant mothers
• Inconsistencies across regions in vaccine uptake rates in different parts of England necessitate strategic intervention
• Community health services tailoring initiatives to align with specific population needs

Real-world impact and parent viewpoints

The vaccine’s outstanding effectiveness translates into real advantages for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the launch of this safeguarding intervention, the 80% decrease in admissions equates to thousands of infants protected against severe infection. Parents no more face the troubling prospect of watching their newborns gasping for air or labour to feed, symptoms that mark severe RSV infections. The vaccine has substantially transformed the terrain of neonatal breathing health, providing expectant mothers a preventative option to protect their most at-risk babies during those crucial first weeks.

For families like that of Malachi, whose serious RSV infection caused devastating brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s promotion of the jab highlights the life-altering consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to expectant mothers during their final trimester, changing what was once an predictable seasonal threat into a manageable health risk.